reports
Meritage Homes Announces Quarterly Cash Dividend
Meritage Homes Announces Quarterly Cash Dividend SCOTTSDALE, Ariz., May 16, 2024 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced that its Board of Directors has declared a quarterly dividend of $0.75 per share. This dividend is payable on June 28, 2024 to shareholders of record as of the close of trading on June 14, 2024. About Meritage Homes Corporation Meritage is the fifth-largest public homebuilder in the United States, based on homes closed in 2023. The Company offers energy-efficien...
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Pr...
Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update — Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery ...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on May 9, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 24 new employees in restricted stock units for an aggregate of 97,557 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units ...
- Wedbush Research
BLUE BLUEBIRD BIO INC.
TPH TRI POINTE HOMES INC.
TOL TOLL BROTHERS INC.
MTH MERITAGE HOMES CORPORATION
LGIH LGI HOMES INC.
LEN LENNAR CORPORATION CLASS A
KBH KB HOME
JACK JACK IN THE BOX INC.
FATE FATE THERAPEUTICS INC
CCS CENTURY COMMUNITIES INC.
BPMC BLUEPRINT MEDICINES CORP.
AZO AUTOZONE INC.
DHI D.R. HORTON INC.
TMHC TAYLOR MORRISON HOME CORPORATION
ORLY O'REILLY AUTOMOTIVE INC.
ACET ADICET BIO INC
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DFH DREAM FINDERS HOMES
NUVB NUVATION BIO INC (A)
TSVT 2SEVENTY BIO INC
GMTX GEMINI THERAPEUTICS INC
PEPG PEPGEN INC
SDHC SMITH DOUGLAS HOMES CORP
- Brian Violino
- Jay McCanless
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch G...
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentatio...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results an...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024 WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 15, 2024, after the close of the stock market. The ...
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nep...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program. Economic modeling by the Institute for Clinical and Economic Review (ICER) in March 2021 demonstrated the cost-effect...
- Soomit Datta
STNE US (Neutral, TP: $20, +20%) StoneCo Q1s - Pretty solid underlying...
StoneCo reported Q1s after close. Having recently updated its accounting for membership fees (negatively affecting revenue and down through the P&L) consensus was, according to IR, a mix of old and new – and not so helpful therefore.
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Reneo Pharmaceuticals and OnKure Announce Proposed Merger Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide funding through multiple clinical milestones and runway into fourth quarter of 2026 IRVINE, Calif., and BOULDER, Colo., May 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) and OnKure, Inc., a privately-held, clinical-stage biopharmac...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase ...
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population - In a pre-specified Cochran-Mantel-Haenszel sensitivity analysis applied to the entire intention-to-treat (ITT) population of the study (N=632), acoramidis significantly reduced all-cause mortality (p=0.04), with no safety signals of potential clinical concern - Among ATTRibute-CM participants...
Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results
Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company’s financial results for the three and six months ended March 31, 2024 and the conference call to discuss the results that were originally scheduled for Friday, May 10, 2024 are being rescheduled to provid...
Meritage Homes Completes Offering of 1.75% Convertible Senior Notes
Meritage Homes Completes Offering of 1.75% Convertible Senior Notes SCOTTSDALE, Ariz., May 09, 2024 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced that it has completed its offering and sale of $575 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028. This amount includes the exercise in full by the initial purchasers of their option to purchase up to an additional $75 million aggregate principal amount of notes. The offering was made to persons reasonably beli...
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for Pe...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12. The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program. A propensity analysis of the A...
Beazer Homes Usa Inc: 1 director
A director at Beazer Homes Usa Inc sold 29,215 shares at 28.680USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Wedbush Research
TXRH TEXAS ROADHOUSE INC.
RNG RINGCENTRAL INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
IMAX IMAX CORPORATION
GLPI GAMING AND LEISURE PROPERTIES INC.
DIN DINE BRANDS GLOBAL INC.
CXW CORECIVIC INC.
CTMX CYTOMX THERAPEUTICS INC.
CAKE CHEESECAKE FACTORY INCORPORATED
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
BJRI BJ'S RESTAURANTS INC.
DRI DARDEN RESTAURANTS INC.
OKTA OKTA INC. CLASS A
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
DDOG DATADOG INC CLASS A
RVMD REVOLUTION MEDICINES
ABNB AIRBNB INC. CLASS A
PHVS PHARVARIS NV
RMBL RUMBLEON INC
APP APPLOVIN CORP
BIRD ALLBIRDS INC
JANX JANUX THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
CART MAPLEBEAR INC.
- Michael Symington
- Nick Setyan
Design Therapeutics Announces First Quarter 2024 Financial Results and...
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinica...
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter ended March 31, 2024. First Quarter and Recent Highlights In December 2023, the pivotal STRIDE study of mavodelpar in adult patients with primary mitochondrial myopathies did not meet its primary efficacy or sec...
Meritage Homes Announces Pricing of Convertible Senior Notes
Meritage Homes Announces Pricing of Convertible Senior Notes SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced the pricing of $500 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2028 (the “notes”). The Company also granted the initial purchasers of the notes a 13-day option to purchase up to $75 million of aggregate principal amount of additional notes. The sale of the notes is expected to settle on May 9, 2024, subject to customar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.